$198.58
Value $266B
RTXvsStrata Critical Medical
RTX and SRTA stock compared: price, dividend, valuation and results, from SEC filings.
+0.11%
$5.51
Value $479M
RTX (RTX) has a market value of $266B and Strata Critical Medical (SRTA) $479M. Over the last year, with dividends, RTX moved +13.4% and SRTA +8.0%. Dividend yield: RTX 1.42%, SRTA none.
At a glance
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
RTX$266B
SRTA$479M
RTX is 556 times SRTA
Revenue, 12 months
RTX$96.0B
SRTA$281M
RTX is 342 times SRTA
Net income, 12 months
RTX$8.4B
SRTA-$25M
Operating margin
RTX11.8%
SRTA-6.6%
18.4 points apart
ROIC
RTX8.8%
SRTA-5.2%
14.0 points apart
P/E
RTX31.7
SRTA–
Dividend yield
RTX1.4%
SRTA0.0%
1.4 points apart
5-year return
RTX+148.8%
SRTA-45.1%
193.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
The price over time
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
RTX+148.8%
SRTA-45.1%
| Period | RTXWith dividends | SRTAWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +13.4%Price +11.8% | +8.0%Price +8.0% |
| 3 years since November 13, 2023 | +157.0%+37.0% a yearPrice +142.1% | +68.0%+18.9% a yearPrice +68.0% |
| 5 years since November 12, 2021 | +148.8%+20.0% a yearPrice +123.5% | -45.1%-11.3% a yearPrice -45.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
Every figure
As on each company's page. A description, not a recommendation: no one figure says which is better.
RTXRTXSRTAStrata Critical Medical
Valuation
RTXSRTA| Price | $198.58 | $5.51 |
|---|---|---|
| Market value | $266B | $479M |
| Enterprise value (EV) | $294B | $438M |
| P/E | 31.7 | – |
| P/E, 5-year median | 33.6 | – |
| P/B | 3.9 | 1.7 |
| EV/EBIT | 26.0 | – |
| Free cash flow yield | 3.6% | 0.2% |
Results and growth
RTXSRTA| Revenue, 12 months | $96.0B | $281M |
|---|---|---|
| Net income, 12 months | $8.4B | -$25M |
| Free cash flow, 12 months | $9.5B | $806.0K |
| Earnings per share, 12 months | $6.16 | -$0.30 |
| Revenue growth, year on year | 9.7% | 34.3% |
| Revenue growth a year, past | +9.4%over 5 years | +53.1%over 5 years |
| EPS growth a year, past | – | – |
Margins and returns on capital
RTXSRTA| Gross margin | – | 21.6% |
|---|---|---|
| Operating margin | 11.8% | -6.6% |
| Net margin | 8.8% | -8.8% |
| ROIC | 8.8% | -5.2% |
| ROE | 12.7% | -8.8% |
Balance sheet
RTXSRTA| Cash | $9.9B | $42M |
|---|---|---|
| Total debt | $38.9B | $3.6M |
| Net debt / EBITDA | 1.8 | – |
| Interest cover | – | – |
Dividends and buybacks
RTXSRTA| Dividend yield | 1.4% | – |
|---|---|---|
| Dividend per share, 12 months | $2.82 | – |
| Dividend growth a year, past | +4.3%over 5 years | – |
| Buyback yield | 0.0% | – |
| Shareholder yield | 1.4% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
Which is bigger, RTX or Strata Critical Medical?
By market value, RTX ($266B) is about 555.7 times Strata Critical Medical ($479M), at today's prices.
How did RTX and SRTA stock do over the last 5 years?
Since November 12, 2021, RTX's price moved +123.5% and SRTA's -45.1%. With dividends: RTX +148.8% (+20.0% a year), SRTA -45.1% (-11.3% a year). Past returns do not predict future ones.
Which pays the higher dividend, RTX or SRTA?
The dividend yield at today's price is 1.42% for RTX and none for Strata Critical Medical. Over the last twelve months they paid $2.82 and – per share.
Which has the higher profit margins, RTX or Strata Critical Medical?
Over the last twelve months, the net margin was 8.8% for RTX and -8.8% for Strata Critical Medical, and the operating margin 11.8% and -6.6%. Revenue was $96.0B and $281M.
Which is the better investment, RTX or Strata Critical Medical?
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
Other comparisons
With each of the two, and with the largest in its sector.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.
Descriptive data from SEC filings and market prices.